AE	Adverse Event
ccRCC	Clear-cell Renal Cell Carcinoma
CI	Confidence Interval
CN	Cytoreductive Nephrectomy
CR	Complete Response
DSP	Digital Spatial Profiling
ECOG	Eastern Cooperative Oncology Group
EMT	Epithelial–Mesenchymal Transition
ERCC	External RNA Controls Consortium
FDR	False Discovery Rate
FFPE	Formalin-Fixed, Paraffin-Embedded
HR	Hazard Ratio
ICAM1	Intercellular Adhesion Molecule 1
ICI	Immune Checkpoint Inhibitor
IMDC	International Metastatic Renal Cell Carcinoma Database Consortium
IO	Immuno-Oncology
IQR	Interquartile Range
ITGAV	Integrin Subunit Alpha V
mRCC	Metastatic Renal Cell Carcinoma
miRNA	MicroRNA
NCCN	National Comprehensive Cancer Network
ORR	Objective Response Rate
OS	Overall Survival
PD	Progressive Disease
PFS	Progression-Free Survival
PR	Partial Response
RECIST	Response Evaluation Criteria in Solid Tumors
ROI	Region of Interest
SD	Stable Disease
TKI	Tyrosine Kinase Inhibitor
TMA	Tissue Microarray
TME	Tumor Microenvironment
TRAE	Treatment-Related Adverse Event
VEGFA	Vascular Endothelial Growth Factor A